Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy

Rasha Abu Eid (Corresponding Author)

Research output: Contribution to journalEditorial

4 Downloads (Pure)

Abstract

Osteosarcoma (OS) is one of the most common primary bone tumors in children and young adults. The majority of osteosarcoma patients have limited alternative therapeutic options and metastatic patients generally have a poor prognosis. Thus, it is important to explore novel effective therapeutic targets in the treatment of osteosarcoma. Diacylglycerol kinase zeta (DGKZ) is a recently identified gene potentially associated with certain human carcinogenesis. However, the role of DGKZ in proliferation of osteosarcoma is still unclear. In this study, DGKZ's expression was firstly investigated in OS tumor samples and correlated with poor outcome in OS patients. Silence of DGKZ by shRNA hampered osteosarcoma cell growth and promoted cell apoptosis in vitro. In vivo, DGKZ's knockout also suppressed xenograft tumor proliferation as determined by bioluminescence imaging and weight/volume measurements. Meanwhile, Affymetrix GeneChip and Ingenuity Pathway Analysis (IPA) revealed that DGKZ knockdown resulted in a decreased activity of MYC pathway, and several target genes expression in MYC pathway were altered, including CCND1, CDKN2B, CDK6, PCNA, and EGR1. Furthermore, immunoprecipitation coupled with mass spectrometry (IP-MS) analysis was used to identify proteins that interacted with DGKZ in OS cells and revealed ERK1/2, a key MYC-interactor, to associate with DGKZ. Together, our study demonstrated that DGKZ might act as an oncogene in osteosarcoma via its possible interaction with ERK1/2 and MYC pathway.

Original languageEnglish
Article number172
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - 19 Mar 2019

Fingerprint

Diacylglycerol Kinase
Osteosarcoma
Head and Neck Neoplasms
Allergy and Immunology
Immunotherapy
MAP Kinase Signaling System
Proliferating Cell Nuclear Antigen
Oncogenes
Immunoprecipitation
Heterografts
Small Interfering RNA
Young Adult
Mass Spectrometry
Neoplasms
Carcinogenesis
Therapeutics
Apoptosis
Gene Expression
Weights and Measures
Bone and Bones

Keywords

  • head and neck cancer
  • cancer immunology
  • immunotherapy
  • immune check point inhibitor
  • cancer vaccine
  • regulatory T (Treg) cell
  • human leukocyte antigen
  • ERK1/2
  • Osteosarcoma
  • MYC
  • Oncogene
  • DGKZ

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy. / Abu Eid, Rasha (Corresponding Author).

In: Frontiers in Oncology, Vol. 9, 172, 19.03.2019.

Research output: Contribution to journalEditorial

@article{487ca0a3ed524b2f98527768dff2adca,
title = "Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy",
abstract = "Osteosarcoma (OS) is one of the most common primary bone tumors in children and young adults. The majority of osteosarcoma patients have limited alternative therapeutic options and metastatic patients generally have a poor prognosis. Thus, it is important to explore novel effective therapeutic targets in the treatment of osteosarcoma. Diacylglycerol kinase zeta (DGKZ) is a recently identified gene potentially associated with certain human carcinogenesis. However, the role of DGKZ in proliferation of osteosarcoma is still unclear. In this study, DGKZ's expression was firstly investigated in OS tumor samples and correlated with poor outcome in OS patients. Silence of DGKZ by shRNA hampered osteosarcoma cell growth and promoted cell apoptosis in vitro. In vivo, DGKZ's knockout also suppressed xenograft tumor proliferation as determined by bioluminescence imaging and weight/volume measurements. Meanwhile, Affymetrix GeneChip and Ingenuity Pathway Analysis (IPA) revealed that DGKZ knockdown resulted in a decreased activity of MYC pathway, and several target genes expression in MYC pathway were altered, including CCND1, CDKN2B, CDK6, PCNA, and EGR1. Furthermore, immunoprecipitation coupled with mass spectrometry (IP-MS) analysis was used to identify proteins that interacted with DGKZ in OS cells and revealed ERK1/2, a key MYC-interactor, to associate with DGKZ. Together, our study demonstrated that DGKZ might act as an oncogene in osteosarcoma via its possible interaction with ERK1/2 and MYC pathway.",
keywords = "head and neck cancer, cancer immunology, immunotherapy, immune check point inhibitor, cancer vaccine, regulatory T (Treg) cell, human leukocyte antigen, ERK1/2, Osteosarcoma, MYC, Oncogene, DGKZ",
author = "{Abu Eid}, Rasha",
year = "2019",
month = "3",
day = "19",
doi = "10.3389/fonc.2019.00172",
language = "English",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy

AU - Abu Eid, Rasha

PY - 2019/3/19

Y1 - 2019/3/19

N2 - Osteosarcoma (OS) is one of the most common primary bone tumors in children and young adults. The majority of osteosarcoma patients have limited alternative therapeutic options and metastatic patients generally have a poor prognosis. Thus, it is important to explore novel effective therapeutic targets in the treatment of osteosarcoma. Diacylglycerol kinase zeta (DGKZ) is a recently identified gene potentially associated with certain human carcinogenesis. However, the role of DGKZ in proliferation of osteosarcoma is still unclear. In this study, DGKZ's expression was firstly investigated in OS tumor samples and correlated with poor outcome in OS patients. Silence of DGKZ by shRNA hampered osteosarcoma cell growth and promoted cell apoptosis in vitro. In vivo, DGKZ's knockout also suppressed xenograft tumor proliferation as determined by bioluminescence imaging and weight/volume measurements. Meanwhile, Affymetrix GeneChip and Ingenuity Pathway Analysis (IPA) revealed that DGKZ knockdown resulted in a decreased activity of MYC pathway, and several target genes expression in MYC pathway were altered, including CCND1, CDKN2B, CDK6, PCNA, and EGR1. Furthermore, immunoprecipitation coupled with mass spectrometry (IP-MS) analysis was used to identify proteins that interacted with DGKZ in OS cells and revealed ERK1/2, a key MYC-interactor, to associate with DGKZ. Together, our study demonstrated that DGKZ might act as an oncogene in osteosarcoma via its possible interaction with ERK1/2 and MYC pathway.

AB - Osteosarcoma (OS) is one of the most common primary bone tumors in children and young adults. The majority of osteosarcoma patients have limited alternative therapeutic options and metastatic patients generally have a poor prognosis. Thus, it is important to explore novel effective therapeutic targets in the treatment of osteosarcoma. Diacylglycerol kinase zeta (DGKZ) is a recently identified gene potentially associated with certain human carcinogenesis. However, the role of DGKZ in proliferation of osteosarcoma is still unclear. In this study, DGKZ's expression was firstly investigated in OS tumor samples and correlated with poor outcome in OS patients. Silence of DGKZ by shRNA hampered osteosarcoma cell growth and promoted cell apoptosis in vitro. In vivo, DGKZ's knockout also suppressed xenograft tumor proliferation as determined by bioluminescence imaging and weight/volume measurements. Meanwhile, Affymetrix GeneChip and Ingenuity Pathway Analysis (IPA) revealed that DGKZ knockdown resulted in a decreased activity of MYC pathway, and several target genes expression in MYC pathway were altered, including CCND1, CDKN2B, CDK6, PCNA, and EGR1. Furthermore, immunoprecipitation coupled with mass spectrometry (IP-MS) analysis was used to identify proteins that interacted with DGKZ in OS cells and revealed ERK1/2, a key MYC-interactor, to associate with DGKZ. Together, our study demonstrated that DGKZ might act as an oncogene in osteosarcoma via its possible interaction with ERK1/2 and MYC pathway.

KW - head and neck cancer

KW - cancer immunology

KW - immunotherapy

KW - immune check point inhibitor

KW - cancer vaccine

KW - regulatory T (Treg) cell

KW - human leukocyte antigen

KW - ERK1/2

KW - Osteosarcoma

KW - MYC

KW - Oncogene

KW - DGKZ

UR - http://www.scopus.com/inward/record.url?scp=85063346095&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/dgkz-acts-potential-oncogene-osteosarcoma-proliferation-through-possible-interaction-erk12-myc-pathw

U2 - 10.3389/fonc.2019.00172

DO - 10.3389/fonc.2019.00172

M3 - Editorial

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 172

ER -